Welgene Biotech Co., Ltd. Statistics
Welgene Biotech Co., Ltd. (6661) Stock Statistics & Valuation Metrics
Total Valuation
Welgene Biotech Co., Ltd. has a market cap or net worth of TWD 372.87M. The enterprise value is TWD 503.13M.
- Market Cap
- TWD 372.87M
- Enterprise Value
- TWD 503.13M
Share Statistics
Welgene Biotech Co., Ltd. has 23,304,249 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 23,304,249
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Welgene Biotech Co., Ltd.’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.02%.
- Return on Equity (ROE)
- 0.00
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- 0.02%
- Return on Capital Employed (ROCE)
- 0.00
- Revenue Per Employee
- 4.70M
- Profits Per Employee
- 16.63K
- Employee Count
- 80
- Asset Turnover
- 0.60
- Inventory Turnover
- 6.31
Valuation Ratios
The current PE Ratio of Welgene Biotech Co., Ltd. is -234.26. Welgene Biotech Co., Ltd.’s PEG ratio is 3.55.
- PE Ratio
- -234.26
- PS Ratio
- 0.93
- PB Ratio
- 1.43
- Price to FCF
- -3.64
- Price to Operating Cash Flow
- 13.38
- PEG Ratio
- 3.55
Income Statement
In the last 12 months, Welgene Biotech Co., Ltd. had revenue of 375.94M and earned 1.33M in profits. Earnings per share was 0.06.
- Revenue
- 375.94M
- Gross Profit
- 129.27M
- Operating Income
- 127.00K
- Pretax Income
- 1.34M
- Net Income
- 1.33M
- EBITDA
- 27.92M
- Earnings Per Share (EPS)
- 0.06
Cash Flow
In the last 12 months, operating cash flow was 29.09M and capital expenditures -131.51M, giving a free cash flow of -102.42M billion.
- Operating Cash Flow
- 29.09M
- Free Cash Flow
- -102.42M
- Free Cash Flow per Share
- -4.21
Dividends & Yields
Welgene Biotech Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -27.47%
- Earnings Yield
- -0.42%
Stock Price Statistics
- Beta
- 0.27
- 52-Week Price Change
- -14.89%
- 50-Day Moving Average
- 16.61
- 200-Day Moving Average
- 17.59
- Relative Strength Index (RSI)
- 43.46
- Average Volume (3m)
- 5,950
Important Dates
Welgene Biotech Co., Ltd. upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
Welgene Biotech Co., Ltd. as a current ratio of 2.21, with Debt / Equity ratio of 80.35%
- Current Ratio
- 2.21
- Quick Ratio
- 1.98
- Debt to Market Cap
- 0.42
- Net Debt to EBITDA
- -0.00
- Interest Coverage Ratio
- 0.04
Taxes
In the past 12 months, Welgene Biotech Co., Ltd. has paid 42.00K in taxes.
- Income Tax
- 42.00K
- Effective Tax Rate
- 0.03
Enterprise Valuation
Welgene Biotech Co., Ltd. EV to EBITDA ratio is 15.68, with an EV/FCF ratio of -4.74.
- EV to Sales
- 1.22
- EV to EBITDA
- 15.68
- EV to Free Cash Flow
- -4.74
- EV to Operating Cash Flow
- 16.67
Balance Sheet
Welgene Biotech Co., Ltd. has TWD 201.99M in cash and marketable securities with TWD 281.15M in debt, giving a net cash position of -TWD 79.17M billion.
- Cash & Marketable Securities
- TWD 201.99M
- Total Debt
- TWD 281.15M
- Net Cash
- -TWD 79.17M
- Net Cash Per Share
- -TWD 3.40
- Tangible Book Value Per Share
- TWD 10.74
Margins
Gross margin is 36.32%, with operating margin of -0.62%, and net profit margin of -0.41%.
- Gross Margin
- 36.32%
- Operating Margin
- -0.62%
- Pretax Margin
- -0.37%
- Net Profit Margin
- -0.41%
- EBITDA Margin
- 7.75%
- EBIT Margin
- -0.03%
Analyst Forecast
The average price target for Welgene Biotech Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 15.25%
- EPS Growth Forecast
- -171.60%
